SEIS & EIS Fund : INVEST NOW
The MEDCAN fund is the first EIS and SEIS Life Sciences and Deep Tech fund targeting the Medical and Pharmaceutical Cannabis sector. The team will invest in UK based companies that have the potential to become leaders in the UK market, and globally.
The team are based in London and Leeds, with a network of global advisors. Óskare Capital advises the fund which is managed by Sapphire Capital Partners. Please follow the link above to complete the application with Sapphire.
High risk. Capital at risk
Óskare fund I : INVEST NOW
Oskare Capital I is the first AIFM and ESG compatible Venture Capital fund with an investment focus on innovative companies and teams in Europe working on novel therapeutics (cannabinoids and other molecules) that target the endocannabinoid system as well as the ‘picks and shovels’ of the associated ecosystem of services and products that support this fast growing global market.
We are the first fund taking this approach and have a unique pipeline of deals. The Fund will invest in startups across the entire value chain (from Seed to Patient) but will not invest in cannabis production or recreational cannabis.
This website is intended to provide general information regarding ÓSKARE CAPITAL our product and services, and other financial information which may be of interest to you. It is not intended to provide exhaustive treatment of any subject dealt with. The information on this website including all research, opinions or other content is not intended to and does not constitute financial, accounting, tax, legal, investment, consulting or other professional advice or services. Before making any decision or taking any action which might affect your personal finances or business you should take appropriate advice from a suitably qualified person. The website may include technical, typographical or other inaccuracies and you are urged to contact us to confirm all information contained on this website before placing any reliance on it. Changes are periodically made to the information on this website. We reserve the right to alter or amend any criteria or information set out in this website without notice. Past performance of any investment or security is not necessarily an indication of future performance. Value of investments may go up as well as down.
The funds and proposed investment strategies mentioned herein will place investors’ capital at risk and investors may not get back the full amount invested. Neither past performance nor any forecast should be considered a reliable indicator of future results.
This website should not be seen as any indication of returns which might be received by investors in the fund advised by ÓSKARE CAPITAL (the “Fund”). Where projections, forecasts, targeted or illustrative returns or related statements or expressions of opinion are given (“Forward Looking Information”) they should not be regarded by any visitor to the website as a guarantee, prediction or definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. A number of factors could cause actual results to differ materially from those in any Forward Looking Information. There can be no assurance that the Fund’s investment strategy or objective will be achieved or that investors will receive a return of the amount invested.•
Nothing on this website is intended to be nor should be construed as an offer to enter into a contractual relationship with you or anyone else, except for these terms and conditions which govern the relationship between us in relation to your use of the website. No information or content contained on this website should be taken as an offer by us. All services offered by us are subject to completion (in the manner required) of the requisite application forms and other documentation and are governed by our relevant terms and conditions. We reserve the right to reject at our absolute discretion any application submitted for services contained on this website. If you make a contract with a third party who is named or referred to on this website, it is your responsibility to ensure that you are comfortable with the terms of that contract and to take legal advice if necessary. This website is qualified in its entirety by reference to the applicable Fund’s offering documentation. OSKARE Capital does not intend to register its Fund’s securities under the U.S. Securities Act of 1933, as amended, and does not anticipate that each Fund will be registered as an investment company under the U.S. Investment Company Act of 1940, as amended, in each case on reliance on one or more exclusions or exemptions from registration under applicable law. This information contained in the website is only for sophisticated investors. Investors shall be required to make certain representations, including but not limited to, their qualifications to invest in the Fund.
Risk to Capital: Investing in start-ups and early-stage businesses involves risks, including illiquidity, lack of dividends, loss of investment and dilution. It should be done only as part of a diversified portfolio. Any investments are targeted exclusively at investors who understand the risks of investing in early-stage businesses and can make their own investment decisions. Any pitches for investment are not offered to the public.
Financial Services Compensation Scheme Disclaimer: Investments made in investee companies via funds managed by Sapphire Capital Partners LLP may be covered by the Financial Services Compensation Scheme (FSCS). For more details, please contact us or refer to their website: https://www.fscs.org.uk.
Oskare Capital [insert number] is an appointed representative of Sapphire Capital Partners LLP (FRN: 565716), who are authorised and regulated by the Financial Conduct Authority.
Oskare Capital is a Paris based advisory firm registered in France with registration number 880 430 582. Registered office at 108 avenue Felix Faure, 75015, Paris.